AstronauTx

AstronauTx is pioneering a disease-modifying strategy for neurodegenerative disorders by targeting the fundamental link between sleep dysregulation and cognitive decline. The company's platform aims to pharmacologically enhance slow wave sleep and its associated slow oscillations, which are critical for memory consolidation and the brain's waste clearance system (glymphatic flow). Backed by experienced leadership from the biotech and pharma sectors and investors like the SV Health Investors' Dementia Discovery Fund, AstronauTx is advancing its pipeline with the goal of slowing cognitive decline in early-stage Alzheimer's disease and other conditions.

A platform focused on pharmacologically enhancing slow wave sleep (SWS) and its associated slow oscillations to improve cognitive function and restore the brain's glymphatic waste clearance system, aiming for disease modification in neurodegenerative disorders.

Total raised: $71M

Competition is emerging but limited. AstronauTx differentiates itself through a specific pharmacological focus on enhancing slow wave sleep quality for disease modification, backed by a team with deep neuroscience and biotech creation experience. Competitors include academic groups using non-pharmacological stimulation and a small number of early-stage biotechs.